SECreport
Form 8-K OPIANT PHARMACEUTICALS, For: Aug 29
Last opiant pharmaceuticals, inc earnings: 11/7 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations: ir.opiant.com/investor-overview
| IMPACT SNAPSHOT | EVENT TIME: | OPNT | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
OPNT alerts
OPNT alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OPNT alerts
High impacting Opiant Pharmaceuticals, Inc news events
Weekly update
A roundup of the hottest topics
OPNT
NEWS
NEWS
- Opiant Pharmaceuticals Inc (NASDAQ: OPNT) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating.[MarketBeat]
- Opiant Pharmaceuticals licenses drinabant from Sanofi for treatment of ACO [Seeking Alpha][Seeking Alpha]
- Opiant Pharmaceuticals Licenses Novel CB-1 Receptor Antagonist for Treatment of Acute Cannabinoid Overdose from Sanofi[GlobeNewswire]
- Opiant Pharmaceuticals announces FDA Orange Book listing for new NARCAN nasal spray patent [Seeking Alpha][Seeking Alpha]
- Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listing for New NARCAN® Nasal Spray Patent[GlobeNewswire]
- More
OPNT
SEC Filings
SEC Filings
- 2/13/19 - Form SC
- 2/4/19 - Form 4
- 1/17/19 - Form 4
- OPNT's page on the SEC website
- More